A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Public ClinicalTrials.gov record NCT05668741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
Study identification
- NCT ID
- NCT05668741
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- VX-522 mRNA therapy Drug
- IVA Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2023
- Primary completion
- Apr 20, 2026
- Completion
- Sep 8, 2026
- Last update posted
- May 21, 2026
2023 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Child Health Research Unit | Birmingham | Alabama | 35233 | — |
| Memorial Health Services on behalf of Long Beach Memorial Medical Center d/b/a Miller Children's Hospital Long Beach | Long Beach | California | 90806 | — |
| Stanford University - Palo Alto - Pulmonology | Palo Alto | California | 94304 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Clinical & Translational Science Unit (CTSU) - Pulmonology | Kansas City | Kansas | 66160 | — |
| PAREXEL International - Baltimore | Baltimore | Maryland | 21225 | — |
| The Johns Hopkins University - Johns Hopkins Hospital - Pulmonology | Baltimore | Maryland | 21287 | — |
| MGH - MGfC Pediatric Cystic Fibrosis Center | Boston | Massachusetts | 02114 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| University of Minnesota -Pulmonology | Minneapolis | Minnesota | 55455 | — |
| St. Louis Children's Hospital - Pulmonology | St Louis | Missouri | 63110 | — |
| UC Health Holmes Hospital | Cincinnati | Ohio | 45220 | — |
| Medical University of South Carolina - Pulmonology | Charleston | South Carolina | 29425 | — |
| University of Utah Hospital - Pulmonology | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05668741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05668741 live on ClinicalTrials.gov.